Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

N-004

Supelco

Naloxone solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

1 ML
CHF 34.00

CHF 34.00

Check Cart for Availability
Richiedi un ordine bulk
Tutte le immagini(1)

Scegli un formato

Cambia visualizzazione
1 ML
CHF 34.00

About This Item

Formula empirica (notazione di Hill):
C19H21NO4
Numero CAS:
465-65-6
Peso molecolare:
327.37
Numero CE:
200-659-6
Numero MDL:
MFCD00242634
Codice UNSPSC:
41116107
ID PubChem:
329818392
NACRES:
NA.24

CHF 34.00

Check Cart for Availability
Richiedi un ordine bulk

Grado

certified reference material

Stato

liquid

Caratteristiche

Snap-N-Spike®/Snap-N-Shoot®

Confezionamento

ampule of 1 mL

Produttore/marchio commerciale

Cerilliant®

Concentrazione

1.0 mg/mL in methanol

tecniche

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

applicazioni

forensics and toxicology

Formato

single component solution

Temperatura di conservazione

2-8°C

Stringa SMILE

Oc1ccc2C[C@H]3N(CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O)CC=C

InChI

1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1
UZHSEJADLWPNLE-GRGSLBFTSA-N

Informazioni sul gene

human ... OPRD1(4985) , OPRK1(4986) , OPRM1(4988)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

Naloxone is an opiate drug used to counter the effects of opioid overdose. This certified solution standard is applicable for use in LC/MS or GC/MS applications such as clinical toxicology and forensic analysis. Naloxone is sold under the trade names Narcan®, Nalone, and Narcan®ti.

Note legali

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Narcan is a registered trademark of Endo Pharmaceuticals Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

P-071

Pain Management Multi-component Opiate Mixture-13 solution, 100 μg/mL each component (10 μg/mL Fentanyl), ampule of 1.0 mL, certified reference material, Cerilliant®

IMPN-007-04

Naloxone N-oxide solution, 100 μg/mL in acetonitrile: water (1:1), ampule of 1 mL, certified reference material, Cerilliant®

N-063

Naloxone-D5 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-924

Nalorphine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

N-115

Naloxone-D5 solution, 1.0 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

N-004S

Naloxone solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

Avvertenze

Danger

Indicazioni di pericolo

H225,H301 + H311 + H331,H370

Classi di pericolo

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organi bersaglio

Eyes,Central nervous system

Codice della classe di stoccaggio

3 - Flammable liquids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

49.5 °F - closed cup

Punto d’infiammabilità (°C)

9.7 °C - closed cup

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 8

1 of 8

Oxymorphone-3-β-D-glucuronide solution 100 μg/mL in methanol: water (1:1), ampule of 1 mL, certified reference material, Cerilliant®

Supelco

O-030

Oxymorphone-3-β-D-glucuronide solution

Naloxone for peak identification European Pharmacopoeia (EP) Reference Standard

Y0000695

Naloxone for peak identification

vibrant-m

BP548

Naloxone hydrochloride

Naloxone-D5-3-β-D-glucuronide solution 100 μg/mL in methanol: water (9:1), certified reference material, ampule of 1 mL, Cerilliant®

Supelco

N-109

Naloxone-D5-3-β-D-glucuronide solution

Noroxycodone hydrochloride solution 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Supelco

N-011

Noroxycodone hydrochloride solution

Salsalate ≥98% (HPLC)

Sigma-Aldrich

SML0070

Salsalate

Naloxone methiodide ≥98% (HPLC), solid

Sigma-Aldrich

N129

Naloxone methiodide

LY 294002

Sigma-Aldrich

19-142

LY 294002

Severe postoperative hyperthermic syndrome after addition of tilidine/naloxone to duloxetine therapy.
Marco Vinetti et al.
Clinical toxicology (Philadelphia, Pa.), 51(6), 516-517 (2013-06-19)
Jason Boland et al.
Clinical medicine (London, England), 13(2), 149-151 (2013-05-18)
Opioids can induce respiratory depression by invoking a centrally mediated decrease in involuntary respiratory rate, which in severe cases can cause a decrease in oxygen saturation. If respiratory depression is opioid induced, both low respiratory rate and low oxygen saturation
Anne M Neumann et al.
Journal of addictive diseases, 32(1), 68-78 (2013-03-14)
Patients with opioid addiction who receive prescription opioids for treatment of nonmalignant chronic pain present a therapeutic challenge. Fifty-four participants with chronic pain and opioid addiction were randomized to receive methadone or buprenorphine/naloxone. At the 6-month follow-up examination, 26 (48.1%)
R Terry Furst
Journal of addictive diseases, 32(1), 53-67 (2013-03-14)
This study explores strategies that Suboxone misusers utilize while in drug treatment. Ethnographic interviews were conducted with 14 patients who had cycled in and out of Suboxone treatment. The objective of the study is to identify strategies implemented by patients
Robert Taylor et al.
Expert opinion on investigational drugs, 22(4), 517-525 (2013-03-15)
Opioid receptor antagonists are well known for their ability to attenuate or reverse the effects of opioid agonists. This property has made them useful in mitigating opioid side effects, overdose and abuse. Paradoxically, opioid antagonists have been reported to produce
Visualizza tutti i documenti correlati

Articoli

Benefits of Ascentis Express Phenyl-Hexyl over Biphenyl for the Separation of Pain Management Opiates

Although both biphenyl and phenyl-hexyl phases can resolve these compounds, the former exhibits excellent peak shape and substantially less silanol-derived ion exchange activity.

Questions

Reviews

No rating value

Active Filters

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.